In March 2025, the market saw the slated launch of Neffy (epinephrine nasal spray), a needle-free alternative for the emergency treatment of allergic reactions (anaphylaxis). Developed to address "needle phobia" and the logistical challenges of auto-injectors, Neffy provides a 1mg dose that achieves plasma concentrations comparable to a $0.3\text{mg}$ intramuscular injection, even in patients with nasal congestion or the common cold.
Technically, the formulation is designed for high stability, with a shelf life of up to 30 months and significant resistance to temperature fluctuations—critical for a life-saving rescue medication. Insights into the "Bioequivalence" testing and the "Orange Book" listing for this product are detailed in the Nasal Spray Market industry report. The shift toward needle-free emergency delivery is expected to increase the carry-rate of epinephrine among at-risk populations, potentially reducing fatalities from accidental allergen exposure.
